Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijgc.2025.102006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Target trial emulation: harnessing real-world data to evaluate surgery and perioperative care interventions.
Br J Surg
September 2025
Department of Vascular Surgery, Bristol Medical School, University of Bristol, Bristol, UK.
Effect of Metformin on the Risk of Post-coronavirus Disease 2019 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study.
Clin Infect Dis
September 2025
Research Department of Practice and Policy, UCL School of Pharmacy, London, United Kingdom.
Background: A subgroup analysis of the COVID-OUT trial's long-term outcome found that starting metformin within 3 days of coronavirus disease 2019 (COVID-19) diagnosis reduced post-COVID-19 condition (PCC) incidence by 63% in overweight or obese individuals. However, its generalizability remains uncertain.
Objectives: To evaluate the effectiveness of metformin in preventing PCC in adults with overweight or obesity who had a recent COVID-19 infection.
Long-term effectiveness of ACE inhibitors or angiotensin receptor blockers in myocardial infarction with preserved left ventricular ejection fraction.
Eur Heart J Cardiovasc Pharmacother
August 2025
Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, 17177 Stockholm, Sweden.
Aims: Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are effective in the long-term treatment of myocardial infarction with reduced left ventricular ejection fraction (LVEF). However, it is unknown whether there is a benefit in myocardial infarction with preserved LVEF (≥50%).
Methods And Results: We used Swedish healthcare registries to emulate a target trial of ACEi/ARBs vs.
Integrating imaging and invasive pressure data into a multi-scale whole-heart model.
J Biomech Eng
August 2025
National Heart and Lung Institute, Imperial College London, London W12 0NN, UK & The Alan Turing Institute, The British Library, London NW1 2DB, UK.
Cardiovascular diseases are the leading cause of death. Clinical data used to decide treatment are hard to integrate and interpret, making optimal treatment selection difficult. Personalised models can be used to integrate clinical data into a physics and physiology-constrained framework, but their clinical application faces limitations due to complex calibration and validation.
View Article and Find Full Text PDFLiberal or restrictive transfusion for veno-arterial extracorporeal membrane oxygenation patients: a target trial emulation using the OBLEX study data.
Crit Care
August 2025
School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Background: The optimal transfusion threshold for patients undergoing venoarterial extracorporeal membrane oxygenation (VA-ECMO) remains uncertain.
Methods: We used data from OBLEX (ClinicalTrials.gov: NCT03714048), an international, prospective, observational study conducted across 12 centres in Australia, Europe, and North America between 2019 and 2022.